Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.49 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188763 | 1.00 | ENPP1 (0.56) | ENPP1EGFREHMT2EHMT1SRC | |
| SCHEMBL2746476 | 0.90 | EHMT2 (0.50) | ENPP1EGFREHMT2EHMT1SRC | |
| SCHEMBL22441436 | 0.87 | KDR (0.60) | ENPP1EGFREHMT2EHMT1SRC | |
| SCHEMBL29354537 | 0.87 | KDR (0.60) | ENPP1EGFREHMT2EHMT1SRC | |
| SCHEMBL5201839 | 0.87 | KDR (0.60) | ENPP1EGFREHMT2EHMT1SRC | |
| SCHEMBL4499366 | 0.87 | ENPP1 (0.62) | ENPP1EGFRSRCPDGFRBPDGFRA | |
| SCHEMBL29387468 | 0.87 | SRC (0.60) | EGFRSRCPDGFRBPDGFRA | |
| SCHEMBL29576504 | 0.87 | SRC (0.60) | EGFRSRCPDGFRBPDGFRA | |
| SCHEMBL359988 | 0.87 | SRC (0.60) | EGFRSRCPDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL6430860 | 0.86 | KDR (0.58) | ENPP1EGFREHMT2EHMT1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988110-B | 4-phenoxy quinoline sulfonylurea compound, intermediate for synthesizing the compound and its preparation method and use | 威海海洋生物医药产业技术研究院有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-9827248-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9695184-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2015142928-A1 | DOSING OF CABOZANTINIB FORMULATIONS | EXELIXIS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2014145693-A1 | METABOLITES OF N-[3-FLUORO-4-({ 6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]QUINOLIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014127214-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | WO | disclosed |
| EP-2220078-B1 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-7795254-B2 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| WO-2009058267-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | ENPP1 4763/4885EGFR 58/4885EHMT2 1530/4885 |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | BDKRB2, BDKRB1, OPRK1 | ENPP1 1496/4885EGFR 1443/4885EHMT2 3962/4885 |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | ENPP1 2392/4885EGFR 1296/4885EHMT2 2280/4885 |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | ENPP1 2070/4885EGFR 829/4885EHMT2 4745/4885 |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | ENPP1 2070/4885EGFR 829/4885EHMT2 4745/4885 |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | ENPP1 2070/4885EGFR 829/4885EHMT2 4745/4885 |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | PCSK9, CFTR, SLC10A1 | ENPP1 972/4885EGFR 2464/4885EHMT2 4531/4885 |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | IDH1, NTRK3, FGFR4 | ENPP1 2628/4885EGFR 232/4885EHMT2 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.